ReviewExpert opinion on drug safety2020
The risk of cardiovascular complications with current obesity drugs.
Review in Expert opinion on drug safety, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Analysis of adverse event reports associated with complementary health products in Singapore from 2017 to 2023.Frontiers in medicine · 2026Article
- Cardiovascular safety of fixed-dose extended-release naltrexone/bupropion in clinical practice.Obesity pillars · 2025Article
- Gamma-aminobutyric acid fermentation and its fermented extracts on α-glucosidase inhibition and anti-obesity effect.Bioprocess and biosystems engineering · 2025Article
- Patient and Cardiologist Perspectives on the Treatment of Patients With Concomitant ASCVD and Obesity.Journal of patient experience · 2025Article
- The body mass index change is associated with death or hemodialysis transfer in Japanese patients initiating peritoneal dialysis.Renal failure · 2023Article
- Review
- Understanding cross-data dynamics of individual and social/environmental factors through a public health lens: explainable machine learning approaches.Frontiers in public health · 2023Article
- Determination of 12 anti-obesity drugs in human plasma by a 96-well protein precipitation plate using HPLC-MS.RSC advances · 2022Article
- Anti-Obesity Effect of Rice Bran Extract on High-Fat Diet-Induced Obese Mice.Preventive nutrition and food science · 2022Article
- Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology.Journal of psychopharmacology (Oxford, England) · 2022Review
- New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation.Frontiers of medicine · 2022Review
- Ghrelin Relieves Obesity-Induced Myocardial Injury by Regulating the Epigenetic Suppression of miR-196b Mediated by lncRNA HOTAIR.Obesity facts · 2022Article
- Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?Current obesity reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
introductionObesity is associated with an increased risk of cardiovascular morbidity and mortality. Four medications are approved by the US Food and Drug Administration (FDA) for chronic weight management when used as an adjunct to a reduced-calorie diet and increased physical activity in adults. These medications result in clinically significant weight losses, as well as improvements in some cardiometabolic risk factors. AREAS COVERED: We briefly review the history of anti-obesity medications (AOMs) as related to cardiovascular safety, and summarize weight loss efficacy and cardiovascular data from clinical trials of orlistat, phentermine/topiramate, naltrexone/bupropion, and liraglutide. EXPERT OPINION: Current AOMs approved for chronic weight management have generally favorable effects on some cardiometabolic parameters. However, the long-term safety of orlistat, phentermine/topiramate, and naltrexone/bupropion on cardiovascular morbidity and mortality have not been established. The cardiovascular safety of liraglutide, at a dose of 1.8 mg/d, was demonstrated in a large randomized outcomes trial in participants with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.